Terms: = Cervical cancer AND GATA3, HDR, 2625, ENSG00000107485, MGC5445, MGC5199, MGC2346
580 results:
1. Dosimetric Comparison of Isodose Surface Volume and Total Reference Air Kerma (TRAK) based Volume in cervical cancer Brachytherapy.
Thimmaiah N; Malavade V; A S UK; S S; Pasha C R T; Vishwanath L
Asian Pac J Cancer Prev; 2024 Feb; 25(2):587-594. PubMed ID: 38415545
[TBL] [Abstract] [Full Text] [Related]
2. Patterns of practice survey for cervical cancer brachytherapy in Morocco.
Chekrine T; Bellefkih FZ; Hatim G; Bouchbika Z; Benchakroun N; Jouhadi H; Tawfiq N; Sahraoui S
Brachytherapy; 2024; 23(2):154-164. PubMed ID: 38311545
[TBL] [Abstract] [Full Text] [Related]
3. Redefining the role of pulsed-dose-rate brachytherapy in cervical cancer treatment using a preplanned approach.
Annede P; Robert C; Espenel S; Dumas I; Chargari C
Brachytherapy; 2024; 23(2):107-114. PubMed ID: 38105154
[TBL] [Abstract] [Full Text] [Related]
4. Dose and fractionation regimen for brachytherapy boost in cervical cancer in the US.
Hsieh K; Bloom JR; Dickstein DR; Hsieh C; Marshall D; Ghiassi-Nejad Z; Raince J; Lymberis S; Chadha M; Gupta V
Gynecol Oncol; 2024 Jan; 180():55-62. PubMed ID: 38052109
[TBL] [Abstract] [Full Text] [Related]
5. Simultaneous catheter and multicriteria optimization for hdr cervical cancer brachytherapy with a complex intracavity/interstitial applicator.
Bélanger C; Aubin S; Lavallée MC; Beaulieu L
Med Phys; 2024 Mar; 51(3):2128-2143. PubMed ID: 38043067
[TBL] [Abstract] [Full Text] [Related]
6. Dosimetric comparison of stereotactic MR-guided radiation therapy (SMART) and hdr brachytherapy boost in cervical cancer.
Dincer N; Ugurluer G; Mustafayev TZ; Serkizyan A; Aydin G; Güngör G; Yapici B; Atalar B; Özyar E
Brachytherapy; 2024; 23(1):18-24. PubMed ID: 38000958
[TBL] [Abstract] [Full Text] [Related]
7. Efficacy of high-dose-rate brachytherapy with different radiation source activities among cervical cancer patients and risk factors for long-term outcomes: A 6-year retrospective study.
Wen F; Li C; Liang B; You J; Li X; Wang J; Liu H; Wang F; Dong Z; Zhang Y
Brachytherapy; 2024; 23(1):35-44. PubMed ID: 37919124
[TBL] [Abstract] [Full Text] [Related]
8. External Beam Radiotherapy Interdigitated with High Dose Rate(hdr) Intracavitary Brachytherapy versus External Beam Radiotherapy followed by Sequential hdr Intracavitary Brachytherapy for Locally Advanced Carcinoma Cervix-Randomized Control Study.
Gupta IJ; Ghosh A; Yadav J; Tuteja JS; Gupta R; Srivastava K; Verma M; Gupta S; Srivastava S; Bhatt MLB
Asian Pac J Cancer Prev; 2023 Oct; 24(10):3441-3445. PubMed ID: 37898849
[TBL] [Abstract] [Full Text] [Related]
9. Interfraction variations in doses at OARs during three-dimensional high dose rate brachytherapy planning of cervix cancer.
Dhaka S; Rajani A; Kumar HS; Sharma N; Jakhar SL; Harsh K
J Cancer Res Ther; 2023; 19(5):1136-1141. PubMed ID: 37787275
[TBL] [Abstract] [Full Text] [Related]
10. The American Brachytherapy Society and Indian Brachytherapy Society consensus statement for the establishment of high-dose-rate brachytherapy programs for gynecological malignancies in low- and middle-income countries.
Grover S; Lichter KE; Likhacheva A; Jang JW; Ning MS; Robin TP; Small W; Kudchadker RJ; Swamidas J; Chopra S; Rai B; Sharma SD; Sharma DN; Kuppusamy T; Yang R; Berger D; Mendez LC; Glaser S; Erickson DL; Chino J; Mourtada F; Abdel-Wahab M; Jhingran A; Simonds H; Mahantshetty U
Brachytherapy; 2023; 22(6):716-727. PubMed ID: 37704540
[TBL] [Abstract] [Full Text] [Related]
11. The population percentile allowance method for determining systematic spatial error tolerances for temporary intensity modulated brachytherapy.
Hopfensperger KM; Adams QE; Kim Y; Wu X; Xu W; Patwardhan K; Flynn RT
Med Phys; 2023 Oct; 50(10):6469-6478. PubMed ID: 37643427
[TBL] [Abstract] [Full Text] [Related]
12. Brachytherapy for targeting the immune system in cervical cancer patients.
Linares I; Berenguer Frances MÁ; Cañas R; Najjari D; Gutiérrez C; Marín S; Comas S; Guedea F; Pujol M
BMC Immunol; 2023 Aug; 24(1):23. PubMed ID: 37559025
[TBL] [Abstract] [Full Text] [Related]
13. A linear optimization model for high dose rate brachytherapy using a novel distance metric.
Mirzavand Boroujeni N; Richard JP; Sterling D; Wilke C
Phys Med Biol; 2023 Aug; 68(17):. PubMed ID: 37489861
[No Abstract] [Full Text] [Related]
14. Dose and secondary cancer-risk estimation of patients undergoing high dose rate intracavitary gynaecological brachytherapy.
Doudoo CO; Gyekye PK; Emi-Reynolds G; Adu S; Kpeglo DO; Nii Adu Tagoe S; Agyiri K
J Med Imaging Radiat Sci; 2023 Jun; 54(2):335-342. PubMed ID: 37087327
[TBL] [Abstract] [Full Text] [Related]
15. Self-configuring nnU-Net for automatic delineation of the organs at risk and target in high-dose rate cervical brachytherapy, a low/middle-income country's experience.
Duprez D; Trauernicht C; Simonds H; Williams O
J Appl Clin Med Phys; 2023 Aug; 24(8):e13988. PubMed ID: 37042449
[TBL] [Abstract] [Full Text] [Related]
16. In-vivo Comparison of Planned and Measured Rectal Doses during Cobalt-60 hdr CT-based Intracavitary Brachytherapy Applications of cervical cancer Using the PTW 9112 Semiconductor Probe.
Johan SK; Lobo D; Athiyamaan MS; Srinivas C; Banerjee S; Abhishek K; Saxena PUP
Asian Pac J Cancer Prev; 2023 Mar; 24(3):897-907. PubMed ID: 36974543
[TBL] [Abstract] [Full Text] [Related]
17. Mesonephric Adenocarcinoma and Mesonephric-like Adenocarcinoma of the Urinary Tract.
Xing D; Liang SX; Gao FF; Epstein JI
Mod Pathol; 2023 Jan; 36(1):100031. PubMed ID: 36788068
[TBL] [Abstract] [Full Text] [Related]
18. Detection of Circulating Tumor Cell-Related Markers in Gynecologic cancer Using Microfluidic Devices: A Pilot Study.
Law KS; Huang CE; Chen SW
Int J Mol Sci; 2023 Jan; 24(3):. PubMed ID: 36768623
[TBL] [Abstract] [Full Text] [Related]
19. Communicating the Gynecologic Brachytherapy Experience (CoGBE): Clinician perceived benefits of a graphic narrative discussion guide.
Avila S; Ruiz MJ; Petereit D; Arya R; Callender B; Hasan Y; Kim J; Lee N; McCall A; Son C; Stack K; Asif S; Besecker T; Juneja A; Li Z; Naik P; Ranka T; Saxena P; Siegfried B; Ichikawa T; Golden DW
Brachytherapy; 2023; 22(3):352-360. PubMed ID: 36681540
[TBL] [Abstract] [Full Text] [Related]
20. Outcomes from a 3-fraction high-dose-rate brachytherapy regimen for patients with cervical cancer.
Williamson CW; Kotha NV; Zou J; Brown D; Scanderbeg D; Rash D; Einck J; Yashar C; Mell LK; Mayadev J
Brachytherapy; 2023; 22(3):317-324. PubMed ID: 36631374
[TBL] [Abstract] [Full Text] [Related]
[Next]
